Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Aug 4:13:924589.
doi: 10.3389/fendo.2022.924589. eCollection 2022.

Surgery for acromegaly: Indications and goals

Affiliations
Review

Surgery for acromegaly: Indications and goals

David P Bray et al. Front Endocrinol (Lausanne). .

Abstract

Acromegaly is a disease that occurs secondary to high levels of GH, most often from a hormone-secreting pituitary adenoma, with multisystem adverse effects. Diagnosis includes serum GH and IGF-1 levels, and obtaining an MRI pituitary protocol to assess for a functional pituitary adenoma. Attempted gross total resection of the GH-secreting adenoma is the gold standard in treatment for patients with acromegaly for a goal of biochemical remission. Medical and radiation therapies are available when patients do not achieve biochemical cure after surgical therapy.

Keywords: acromegaly; adenoma; endonasal; endoscopic; pituitary; skull-base; transnasal.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Depiction of Knosp definitions of cavernous sinus invasion (31). Please see Table 1 for descriptions of the Knosp grades.
Figure 2
Figure 2
A 33-year-old man with a GH-secreting microadenoma. Preoperative MRI, T1-post gadolinium contrast, featuring sagittal (A) and coronal (B) views that demonstrate a small adenoma, confined to the pituitary sella. 3-month postoperative MRI, T1-post gadolinium contrast, sagittal (C) and coronal (D) views show gross total resection of the lesion, with well-vascularized nasoseptal flap. More than 1 year from surgery, there is no residual tumor as demonstrated by the sagittal (E) and coronal (F) MRI T1-post gadolinium contrast. The patient achieved biochemical cure after resection of the GH-secreting adenoma.
Figure 3
Figure 3
A 43-year-old woman with a giant GH-secreting pituitary adenoma. Preoperative MRI, T1-post gadolinium contrast, featuring sagittal (A) and coronal (B) reveal a massive, invasive tumor, invading into the brain parenchyma, bilateral cavernous sinuses, and clivus. The T2 coronal sequence (C) shows the invasion into the right frontal lobe. Immediate postoperative MRI, T1-post gadolinium contrast, sagittal (D) and coronal (E) views shows radical resection of tumor, with scant residual in the cavernous sinus. A fat graft and nasoseptal flap were employed. 1-year postoperative there is a small amount of residual tumor in the cavernous sinuses, as demonstrated by the sagittal (F) and coronal (G) MRI T1-post gadolinium contrast. The patient achieved biochemical remission after initiation of octreotide. No radiation was needed.
Figure 4
Figure 4
A 40-year-old man with a recurrent GH-secreting macroadenoma. His first surgery was completed at an outside institution. Preoperative MRI, T1-post gadolinium contrast, featuring sagittal (A) and coronal (B) views that show a macroadenoma with bilateral Knosp 3 invasion into the cavernous sinuses. 3-month postoperative MRI, T1-post gadolinium contrast, sagittal (C) and coronal (D) views show radical resection of the lesion, with very small residual in the left Knosp 3A compartment. More than 1 year from surgery, there is stable residual tumor in the left cavernous sinus as demonstrated by the sagittal (E) and coronal (F) MRI T1-post gadolinium contrast. The patient achieved biochemical remission with lanreotide.

References

    1. Scacchi M, Cavagnini F. Acromegaly. Pituitary (2006) 9(4):297–303. doi: 10.1007/s11102-006-0409-4 - DOI - PubMed
    1. Laws ER, Vance ML, Thapar K. Pituitary surgery for the management of acromegaly. Horm Res (2000) 53(Suppl 3):71–5. doi: 10.1159/000023538 - DOI - PubMed
    1. Holdaway IM, Bolland MJ, Gamble GD. A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol (2008) 159(2):89–95. doi: 10.1530/EJE-08-0267 - DOI - PubMed
    1. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, et al. . A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab (2010) 95(7):3141–8. doi: 10.1210/jc.2009-2670 - DOI - PubMed
    1. Marquez Y, Tuchman A, Zada G. Surgery and radiosurgery for acromegaly: A review of indications, operative techniques, outcomes, and complications. Int J Endocrinol (2012) 2012:1–7. doi: 10.1155/2012/386401 - DOI - PMC - PubMed

Publication types

MeSH terms